Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $98000.0.

  • CytomX Therapeutics' Depreciation & Amortization (CF) fell 7506.36% to $98000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 3315.63%. This contributed to the annual value of $1.6 million for FY2024, which is 2005.91% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Depreciation & Amortization (CF) is $98000.0, which was down 7506.36% from $310000.0 recorded in Q2 2025.
  • CytomX Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $643000.0 during Q3 2021, with a 5-year trough of $98000.0 in Q3 2025.
  • Its 5-year average for Depreciation & Amortization (CF) is $487631.6, with a median of $559000.0 in 2023.
  • As far as peak fluctuations go, CytomX Therapeutics' Depreciation & Amortization (CF) surged by 921.5% in 2021, and later crashed by 7506.36% in 2025.
  • CytomX Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $639000.0 in 2021, then fell by 10.49% to $572000.0 in 2022, then decreased by 21.5% to $449000.0 in 2023, then dropped by 16.26% to $376000.0 in 2024, then crashed by 73.94% to $98000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $98000.0 for Q3 2025, versus $310000.0 for Q2 2025 and $349000.0 for Q1 2025.